Literature DB >> 15539945

Hepsin paradox reveals unexpected complexity of metastatic process.

Valeri Vasioukhin1.   

Abstract

The existing models of cancer progression assume that a linear sequence of genetic and epigenetic events occurs during this process. In this representation every new event (either loss of a tumor-suppressor, or activation of a proto-oncogene) makes cells even more malignant. The result is a "super" cell that can form metastases at the distant sites. Metastatic cells are believed to carry all genetic and epigenetic characteristics that are necessary for metastasis formation. Recently, we have shown that cell-surface protease hepsin causes disorganization of the basement membrane and promotes prostate cancer progression and metastasis. In human prostate cancer hepsin is upregulated in the precancerous lesions and this upregulation is maintained in the primary tumors. Remarkably and completely unexpected for a metastasis-promoting gene, hepsin is expressed at low levels in metastatic lesions and the message is completely absent in metastasis-derived prostate cancer cell lines. These results demonstrate that genes that play an important role in metastatic process may exercise their role only at the specific fragments of cancer progression pathway (for example, during initial invasion and tissue disorganization in the primary organ) and may have no role in metastatic lesions. Future treatment of cancer patients may rely heavily on monitoring of tumor progression, as treatment efficient in attenuation of initial tumor progression may be inefficient or even adverse at the advance stages of disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15539945     DOI: 10.4161/cc.3.11.1273

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  10 in total

1.  Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells.

Authors:  Stephanie M Wittig-Blaich; Lukasz A Kacprzyk; Thorsten Eismann; Melanie Bewerunge-Hudler; Petra Kruse; Eva Winkler; Wolfgang S L Strauss; Raimund Hibst; Rudolf Steiner; Mark Schrader; Daniel Mertens; Holger Sültmann; Rainer Wittig
Journal:  Neoplasia       Date:  2011-07       Impact factor: 5.715

2.  Detection of early prostate cancer using a hepsin-targeted imaging agent.

Authors:  Kimberly A Kelly; Sunita R Setlur; Robert Ross; Rajesh Anbazhagan; Peter Waterman; Mark A Rubin; Ralph Weissleder
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

3.  Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers.

Authors:  Sylvia Herter; Derek E Piper; Wade Aaron; Timothy Gabriele; Gene Cutler; Ping Cao; Ami S Bhatt; Youngchool Choe; Charles S Craik; Nigel Walker; David Meininger; Timothy Hoey; Richard J Austin
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

4.  Implication of Hepsin from Primary Tumor in the Prognosis of Colorectal Cancer Patients.

Authors:  David Zaragoza-Huesca; Andrés Nieto-Olivares; Francisco García-Molina; Guillermo Ricote; Sofía Montenegro; Manuel Sánchez-Cánovas; Pedro Garrido-Rodríguez; Julia Peñas-Martínez; Vicente Vicente; Francisco Martínez; María Luisa Lozano; Alberto Carmona-Bayonas; Irene Martínez-Martínez
Journal:  Cancers (Basel)       Date:  2022-06-24       Impact factor: 6.575

5.  Identification and characterization of small-molecule inhibitors of hepsin.

Authors:  John R Chevillet; Gemma J Park; Antonio Bedalov; Julian A Simon; Valeri I Vasioukhin
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

6.  Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.

Authors:  Manisha Tripathi; Srinivas Nandana; Hironobu Yamashita; Rajkumar Ganesan; Daniel Kirchhofer; Vito Quaranta
Journal:  J Biol Chem       Date:  2008-09-09       Impact factor: 5.157

7.  Hepsin activates prostasin and cleaves the extracellular domain of the epidermal growth factor receptor.

Authors:  Mengqian Chen; Li-Mei Chen; Chen-Yong Lin; Karl X Chai
Journal:  Mol Cell Biochem       Date:  2010-04       Impact factor: 3.396

8.  Association of hepsin gene variants with prostate cancer risk and prognosis.

Authors:  Sarah K Holt; Erika M Kwon; Daniel W Lin; Elaine A Ostrander; Janet L Stanford
Journal:  Prostate       Date:  2010-06-15       Impact factor: 4.104

9.  Inference of disease-related molecular logic from systems-based microarray analysis.

Authors:  Vinay Varadan; Dimitris Anastassiou
Journal:  PLoS Comput Biol       Date:  2006-06-16       Impact factor: 4.475

10.  Low expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survival.

Authors:  Mikko Pelkonen; Kaisa Luostari; Maria Tengström; Hermanni Ahonen; Bozena Berdel; Vesa Kataja; Ylermi Soini; Veli-Matti Kosma; Arto Mannermaa
Journal:  BMC Cancer       Date:  2015-05-27       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.